It is better to be in a clinical trial than not: Lessons learnt from clinical neurology-the management of acute multiple sclerosis relapses

QJM: An International Journal of Medicine

Volumn 105, Issue 8, 2012, Pages 775-780

  McNicholas, N ^a,b   Patel, A ^a   Chataway, J ^a,c  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPREDNISOLONE;

ADULT; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; FEMALE; HEALTH CARE ACCESS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; MULTIPLE SCLEROSIS; NEUROLOGY; OUTPATIENT DEPARTMENT; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; TREATMENT OUTCOME;

EID: 84865115854     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcs070     Document Type: Article

References (13)

1. Vist GE, Bryant D, Somerville L, Birminghem T, Oxman AD. Outcomes of patients who participate in randomized controlled trials compared to similar patients receiving similar interventions who do not participate. Cochrane Database Syst Rev 2008;(3): MR000009.
2. Braunholtz DA, Edwards SJ, Lilford RJ. Are randomized clinical trials good for us (in the short term)? Evidence for a 'trial effect'. J Clin Epidem 2001; 54:217-24.
3. Peppercorn JM, Weeks JC, Cook EF, Joffe S. Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet 2004; 363:263-70.
4. Kerr DJ, Knox K, Robertson DC, Stewart D, Watson R, eds, Patient's Reasons for Participation in Clinical Trials and Effect of Trial Participation on Patient Outcomes. ECRI evidence report. Plymouth Meeting, PA 19462, ECRI, 2002. [http://www.ecri.org].
5. NICE. Management of Multiple Sclerosis in Primary and Secondary Care. National Institute for Clinical Excellence Clinical Guideline. 2003; 8:1-64. [www.nice.org.uk] (31 March 2012, date last accessed).
6. Porter B, Matheson F, Chataway J. Key Steps to Delivery of a Person Centred Relapse Service. Multiple Sclerosis Trust, 2010: [www.mstrust.org.uk/publications/] (31 March 2012, date last accessed).
7. Chataway J, Porter B, Riazi A, Heaney D, Watt H, Hobart J, et al. Home versus outpatient administration of intravenous steroids for multiple-sclerosis relapses: a randomized controlled trial. Lancet Neurol 2006; 5:565-71.
8. Riazi A, Porter B, Chataway J, Thompson A, Hobart J. Developing a measure of patient's experience of relapse management in multiple sclerosis. Mult Scler 2003; 9:s152.
9. Riazi A, Porter B, Chataway J, Thompson AJ, Hobart JC. A tool to measure the attributes of receiving IV therapy in a home versus hospital setting: the Multiple Sclerosis Relapse Management Scale (MSRMS). Health Qual Life Outcomes 2011; 9:80.
10. Grimshaw JM, Russell IT. Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations. Lancet 1993; 342:1317-22.
11. Leonard KL. Is patient satisfaction sensitive to changes in the quality of care? An exploitation of the Hawthorne effect. J Health Econ 2008; 27:444-59.
12. Department of Health. The National Service Framework for Long term Conditions2005; 1-81. [http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4105361] (31 March 2012, date last accessed).
13. Taking Control. A report by the Neurological Alliance, the Association of the British Pharmaceutical Industry (ABPI) and Ask About Medicines. 2008; 1-24. [http://www.neural.org.uk/publications-and-resources] (31 March 2012, date last accessed)